Key Highlights
- Net income for Q1 reached $745 million, representing an increase from $654 million in the prior year period
- Quarterly revenue totaled $6.02 billion, falling below Wall Street’s $6.35 billion projection
- Adjusted earnings per share of $2.60 came in under the Street consensus of $2.98
- A March cyber incident linked to Iranian hackers created operational challenges and affected financial performance
- Shares of SYK declined approximately 2% in extended trading to $308.75; company reaffirmed annual projections
The medical technology company delivered mixed first-quarter performance, showing improved profitability compared to last year while falling short of analyst expectations on both revenue and earnings. The quarter’s outcomes were significantly influenced by a cybersecurity breach that occurred in March.
Shares of SYK retreated roughly 2% in after-hours trading, settling at $308.75 after the earnings announcement.
The medical device manufacturer reported net income of $745 million, translating to $1.93 per share, compared with $654 million, or $1.69 per share, during the same quarter last year. After adjustments, earnings came to $2.60 per share, below the analyst consensus of $2.98.
Quarterly sales reached $6.02 billion for the period ending March 31. While this represented a 2.6% gain from the year-ago quarter, it underperformed the Street’s $6.35 billion forecast.
Cybersecurity Breach Impacted Performance
During March, a hacking collective known as Handala, reportedly connected to Iran, took credit for launching a damaging cyber assault against Stryker. The breach triggered extensive disruptions across the company’s Microsoft infrastructure and allegedly postponed certain surgical operations.
Multiple employees and external workers shared on social platforms that the hacker group’s emblem surfaced on their system login pages, although Reuters could not independently confirm these accounts.
The medical technology firm had previously indicated in early April that the cybersecurity incident would negatively affect its first-quarter financial outcomes. Management confirmed this impact during Thursday’s earnings release.
According to a Wall Street Journal report from that period, the attackers stated they were responding to heightened tensions between the United States and Iran.
Business Unit Performance Varied
Stryker’s MedSurg and Neurotechnology division, which represents its biggest business unit, generated a 5% revenue gain to $3.21 billion. However, this figure trailed analyst projections of $3.83 billion.
The Orthopaedics division delivered a stronger performance. Revenue in this segment climbed 6.3% to $2.81 billion, surpassing analyst expectations of $2.51 billion.
Weaker market demand for implants and medical devices utilized in sophisticated procedures — such as spinal surgeries and orthopedic operations — contributed to the overall revenue shortfall.
The company faces direct competition from Zimmer Biomet (ZBH) and Johnson & Johnson (JNJ) in the orthopedics sector, spanning categories including hip and knee replacement systems, trauma products, and sports medicine solutions.
Notwithstanding the quarterly challenges, Stryker maintained its full-year financial outlook. Management confirmed its expectations for adjusted annual earnings between $14.90 and $15.10 per share.
By preserving its annual guidance, leadership is communicating confidence that the cybersecurity incident’s financial consequences are limited to the first quarter and won’t materially affect full-year performance.
With adjusted earnings of $2.60 in Q1 against full-year guidance of $14.90–$15.10 per share, the company is projecting accelerated earnings momentum throughout the final three quarters.
Management stood by its full-year adjusted earnings per share forecast of $14.90 to $15.10.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
